Innate Pharma: cash flow horizon to end-2025

(CercleFinance.com) - Innate Pharma announced on Wednesday that it had E96.
4m in cash and cash equivalent at 30 September, providing it with a cash horizon until the end of 2025. NB: cp -5.6%.

In a reaction note, analysts at Oddo BHF consider that, in view of this sum, the company is "perfectly financed to achieve its short-term catalysts".

As a reminder, Innate recently achieved several important regulatory milestones, notably by obtaining an encouraging preliminary response from the US FDA concerning its regulatory strategy for lacutamab (lymphomas).

The company has also been authorised to initiate clinical development of IPH4502, its ADC targeting Nectin-4 expressing tumors.

In the first 9m of the year, sales totaled E10.2m, compared with E36.5m in the first 9m of 2023.

These revenues are mainly derived from the partial or full recognition of payments received under collaboration and licensing agreements with AstraZeneca and Sanofi.

Innate recently appointed Jonathan Dickinson as Chairman of the Management Board, replacing co-founder Hervé Brailly, an appointment which took effect on 1 November.

However, Innate shares were down over 5% in the wake of this publication.


Copyright (c) 2024 CercleFinance.com. All rights reserved.